1. US National Library of Medicine. ClinicalTrials.gov: Cannabis studies. Accessed September 1, 2021: https://clinicaltrials.gov/ct2/results?cond=&term=Cannabis&cntry=&state=&city=&dist=
  2. Di Marzo V, Piscitelli F. The endocannabinoid system and its modulation by phytocannabinoids. 2015 Oct;12(4): 692-8.
  3. Häuser W, Finn DP, Kalso E, et al. European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management. Eur J Pain. 2018 Oct;22(9): 1547-64.
  4. Centonze D. Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity nervous pathways. Eur Neurol. 2014 Sep;72 Suppl 1: 6-8.
  5. Solari A, Giordano A, Sastre-Garriga J, et al. EAN guideline on palliative care of people with severe, progressive multiple sclerosis. Eur J Neurol. 2020 Aug;27(8): 1510-29.
  6. Ezeoke CC, Morley JE. Pathophysiology of anorexia in the cancer cachexia syndrome. J Cachexia Sarcopenia Muscle. 2015 Dec;6(4): 287-302.
  7. Martin BR, Wiley JL. Mechanism of action of cannabinoids: how it may lead to treatment of cachexia, emesis, and pain. J Support Oncol. 2004 Jul-Aug;2(4): 305-14; discussion 314-6.
  8. Tramèr MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. 2001 Jul;323(7303): 16-21.
  9. Perucca E. Cannabinoids in the treatment of epilepsy: hard evidence at last? J Epilepsy Res. 2017 Dec;7(2): 61-76.
Ritornare a...
Perché - Doentes